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Abstract
Background: There is a widespread notion, based on limited information, that in areas of stable malaria
transmission most pregnant women with Plasmodium falciparum infection are asymptomatic. This study aim
to characterize the clinical presentation of malaria in African pregnant women and to evaluate the
adequacy of case management based on clinical complaints.
Methods: A hospital-based descriptive study between August 2003 and November 2005 was conducted
at the maternity clinic of a rural hospital in Mozambique. All women attending the maternity clinic were
invited to participate. A total of 2,330 women made 3,437 eligible visits, 3129 were analysed, the
remainder were excluded because diagnostic results were unavailable or they were repeat visits. Women
gave a standardized clinical history and had a medical exam. Malaria parasitaemia and haematocrit in
capillary blood was determined for all women with signs or symptoms compatible with malaria including:
presence and history of fever, arthromyalgias, headache, history of convulsions and pallor. Outcome
measure was association of malaria symptoms or signs with positive blood slide for malaria parasitaemia.
Results: In 77.4% of visits pregnant women had symptoms suggestive of malaria; 23% (708/3129) were in
the first trimester. Malaria parasitaemia was confirmed in 26.9% (842/3129) of visits. Headache,
arthromyalgias and history of fever were the most common symptoms (86.5%, 74.8% and 65.4%)
presented, but their positive predictive values for malaria parasitaemia were low [28% (27–30), 29%
(28–31), and 33% (31–35), respectively].
Conclusion: Symptoms suggestive of malaria were very frequent among pregnant women attending a
rural maternity clinic in an area of stable malaria transmission. However, less than a third of them were
parasitaemic. In the absence of microscopy or rapid diagnostic tests, a large proportion of women,
including those in the first trimester of gestation, would be unnecessarily receiving antimalarial drugs, often
those with unknown safety profiles for pregnancy. Accessibility to malaria diagnostic tools needs to be
improved for pregnant women and drugs with a safety profile in all gestational ages are urgently needed.
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Background
Each year 25 million African women become pregnant in
malaria endemic areas [1]. In most of these settings
malaria transmission is stable and Plasmodium falciparum
is predominant [2]. Primigravidae women have the high-
est risk for malaria infection [3,4]. Malaria infections are
associated with maternal anaemia, low birth weight and
premature delivery [5-8]. Despite this well-documented
indirect morbidity burden, it is generally assumed that
due to the acquisition of significant levels of anti-malarial
immunity in areas of stable transmission, parasitaemic
pregnant women are rarely symptomatic, and that severe
disease or death from malaria is extremely unusual [9].
However, this assumption is based on a few studies car-
ried out among women attending antenatal clinics
(ANCs) for routine examination and on cross-sectional
community studies, which tend to underestimate the
actual frequency of malaria-related symptoms [10,11].
This misrepresentation of the problem's magnitude has
affected resource prioritisation for malaria control in preg-
nancy in many African countries http://rbm.who.int/
amd2003/amr2003/pdf/ch4.pdf.
Another widely accepted assumption is that women rarely
present with malaria-related clinical complaints during
the first trimester of pregnancy. As chloroquine (CQ) is
being phased out to treat uncomplicated malaria, little
attention has been paid to ensuring the availability of
antimalarial drugs that could be safely administered dur-
ing this critical period of pregnancy. The current recom-
mendation for the treatment of malaria episodes in the
first trimester is oral quinine for seven days [12]. How-
ever, the effectiveness of this regimen is likely to be low
due to the frequency of side effects related to quinine and
the low compliance with such a lengthy regimen.
A hospital-based descriptive study was carried out in rural
Mozambique to document the frequency that pregnant
women present with clinical complaints suggestive of
malaria and to assess their parasitological confirmation.
The study aimed to characterize the clinical presentation
of malaria in African pregnant women and to understand
the extent that current case management based on clinical
complaints is an adequate strategy in pregnancy, espe-
cially in the context of new, less safe and more expensive
antimalarial drugs.
Methods
Study area and population
The study was conducted in Manhiça (Manhiça District,
Maputo Province), a rural area in southern Mozambique.
The characteristics of the area have been described in
detail elsewhere [13]. The area has a population of
approximately 82,000 inhabitants, who are under contin-
uous Demographic Surveillance (DSS) carried out by the
Centro de Investigação em Saúde de Manhiça (CISM)
(Manhica Health Research Center). The adjacent Manhiça
Health Centre (MHC) is a 110-bed health facility that
offers preventive and curative services. Eighty percent of
the pregnant women in this area have an institutional
delivery and more than 90% attend the ANC at least once
during pregnancy [Nhacolo, personal communication].
The ANC also provides curative services to pregnant
women when they are sick.
Perennial malaria transmission with pronounced season-
ality is mostly attributable to P. falciparum. Anopheles
funestus is the main vector, and the estimated entomolog-
ical inoculation rate for 2002 was 38 infective bites per
person per year [14]. In Manhiça, RIII resistance to CQ in
children was 30% in 1999 [15]. Previous data from this
area showed that sulphadoxine-pyrimethamine (SP) in
children had a therapeutic efficacy (adequate clinical
response) of 83%, with an in vivo parasitological sensitiv-
ity of 83,6% at day 14 [16]. According to data from 2006,
the fertility rate is 4.6, the maternal mortality ratio 820 per
100,000 live births and the life expectancy 42.9 (Nhacolo,
unpublished). Insecticide-treated net (ITN) coverage at
the time of the study was zero [17].
The current Mozambican policy for malaria prevention in
pregnancy relies on ITN use and, more recently, intermit-
tent preventive treatment (IPTp) with SP. However, at the
time of the study, none of these measures were recom-
mended yet. Malaria control during pregnancy relied
solely on presumptive treatment of clinical episodes with
CQ or SP in the first and subsequent trimesters for
uncomplicated malaria, respectively, and with parenteral
quinine for severe malaria.
The study protocol was approved by the National Mozam-
bican Ethics Committee and the Hospital Clinic of Barce-
lona Ethics Review Committee.
Study design
Between August 2003 and November 2005, a morbidity
surveillance system was established at the MHC maternity
clinic, as a passive case detection system, for all women
(pregnant, puerperal and women with gynaecological
complaints) attending this clinic with clinical complaints
(i.e., not for those attending the routine antenatal clinic).
During the visit, after verbal informed consent was
obtained, the maternity staff recorded the clinical and
demographic information onto a standardized question-
naire. Health staff recorded information on age, parity,
gestational age, axillary temperature, and signs and symp-
toms focused on malaria. A capillary blood sample for
quantifying P. falciparum parasitaemia and haematocrit
was collected if women reported at least one pre-defined
clinical criteria suggestive of malaria. The clinical criteriaMalaria Journal 2008, 7:27 http://www.malariajournal.com/content/7/1/27
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included: axillary temperature ≥ 37.5°C, reported history
of fever in the last 24 hours, pallor, arthromyalgias, head-
ache and/or history of convulsions. Project staff was avail-
able 24 hours a day to identify women and to ensure
adequate documentation and clinical management.
Women with a blood slide positive for malaria were
treated with SP plus CQ in cases of non-complicated
malaria (in the first trimester CQ alone was given). Oral
quinine for 7 days was given as the second line treatment.
Women with complicated malaria were admitted to the
maternity ward and treated with parenteral quinine fol-
lowed by SP. Anaemia was treated following national
guidelines with oral ferrous sulphate and folic acid for one
month.
Laboratory methods
Duplicate thick and thin blood films were Giemsa-stained
and read to determine parasite species and density of P.
falciparum asexual stages according to standard, quality-
controlled procedures [18]. The haematocrit was meas-
ured using a microhaematocrit centrifuge and read in a
Hawksley (Lancing, UK) haematocrit reader.
Statistical methods and definitions
Double data entry, validation and cleaning were done
using Microsoft Visual FoxPro 5.0, and statistical analysis
was performed using STATA.8.2 (STATA Corporation,
College Station, TX, USA). Differences between propor-
tions were compared using the X2 or Fisher's exact test. To
evaluate the association between the presence or history
of fever, headache, arthromyalgias, convulsions, pallor,
age, parity, gestational age, number of previous malaria
episodes and season with parasitaemia, multivariate logis-
tic regression models were used. Covariates were selected
using a stepwise methodology with a p value of 0.10 for
removal and 0.05 for addition to the model. The stratum
specific significance tests were yielded by Wald test. Miss-
ing values were coded as such and excluded from analysis.
A malaria episode was defined as a P. falciparum parasitae-
mia of any density and signs and/or symptoms suggestive
of malaria (fever or history of fever in the last 24 hours,
headache, arthromyalgias, and/or pallor), but without
severe anaemia, history of convulsions or high-density
parasitaemia. For the purpose of the analysis, the duration
of any single malaria episode was estimated as 28 days, in
order to distinguish between visits on the same episode
and a new one. Moderate anaemia in the pregnant woman
was defined as a PCV (packed cell volume) between 21%
and 32%. Severe anaemia was defined as a PCV between
16% and 20%, and very severe anaemia as a PCV lower
than 16%.
During the study period 4957 visits were made to the
maternity clinic (Figure 1). Of them 517 (10.4%) were
made by non-pregnant women (puerperal and women
with gynaecological complaints) and were not included in
this analysis. Of the 4440 visits made by pregnant women
3437 (77.4%) visits had criteria for blood collection. Of
these, in 229 visits whether the parasitaemia or the hae-
matocrit result was not available and 79 was the second
visit of the same episode. This paper reports findings on
3129 first or only visits of the same episode made by preg-
nant women with criteria for blood collection and com-
plete laboratory results.
Results
Characteristics of visits made by pregnant women
Demographic characteristics of visits to the maternity
clinic are shown in Table 1. Nearly a quarter of the visits
were made in the first trimester, and 12.9% were women
in their first pregnancy. More women came during the wet
season than in the dry season. Fever or history of fever was
found in more than half (65.3%; 2044/3129) of all cases,
while current fever was present in only 12.1% (377/
3129). Arthromyalgias and headache were reported in
74.8% (2339/3129) and 86.5% (2706/3129) of the visits,
respectively. Convulsions were reported in just 0.4% (13/
3129) and pallor was found in 7% (218/3129) of the vis-
its (Table 1).
Table 2 shows the proportion of P. falciparum parasitae-
mia and anaemia in the 3,129 visits analysed. Malaria par-
Profile of the study Figure 1
Profile of the study.
4440 visits by
pregnant women
1,003 (22.6%) visits without
criteria for blood collection:
•  25 second visits
•  978 first or only visits
3,129 visits analysed
4,957 visits to the
maternity clinic
517 visits by
non- pregnant women
(puerperal and
gynecological complaints)
3,437 (77.4%) visits
with criteria for blood
collection
308 visits excluded:
•  229 visits without complete
laboratory results
•  79 second visitsMalaria Journal 2008, 7:27 http://www.malariajournal.com/content/7/1/27
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asites were found in 26.9% (842/3,129) of the visits while
overall anaemia was observed in 56.1% (1755/3,129).
Severe or very severe anaemia were found in 3.1% (96/
3,129) of the visits.
Frequency of visits and malaria episodes per woman
The frequency of visits to the maternity clinic is shown in
Table 3. The average number of visits per woman was 1.34
(SD 0.73). Nearly a quarter (23.8%; 554/2,330) of the
women came more than once to the clinic. There were
0.36 (SD 0.55) malaria episodes per woman, and over a
third (32.9%; 765/2,330) of them had one or more
malaria episodes, contributing to a total of 842 episodes.
The mean number of visits per malaria episode was 1.09
(SD 0.30). In 75 (8.9%) out of 842 episodes, the women
came at least twice. Women were admitted to hospital in
19.1% (597/3,129) of the outpatients visits made to the
maternity clinic. In 22 visits (0.7%; 22/3,129) the women
were referred to another hospital, and the rest were sent
home. Forty-three percent (361/842) of the malaria epi-
sodes required hospital admission. Chloroquine was
given in 321 (38.1%) of the 842 malaria episodes, qui-
nine in 365 (43.3%), SP in 610 (72.4%) and amodi-
aquine in 12 (1.4%). Frequently more than one
antimalarial drug was prescribed.
Risk factors associated with P. falciparum clinical malaria 
in pregnant women
In both the univariate and multivariate analyses, younger
age, primigravidae, second and third trimester of gesta-
tional age and wet season were all statistically significantly
associated with an increased risk of clinical malaria (Table
4). Having had a previous malaria episode was also inde-
pendently associated with a significantly increased risk of
malaria parasitaemia. The prevalence of visits with pres-
ence of signs and/or symptoms suggestive of malaria
increased significantly with increased parasite density.
Table 5 shows the prevalence and positive predictive val-
ues (the probability that a person with a positive test, in
this case presenting a sign or symptoms, is a true positive)
Table 3: Frequency of visits to the maternity clinic and malaria 
episodes per woman
N = 2330*
n%
Visits per woman 1 visit 1776 76.2
2 visits 395 17.0
≥ 3 visits 159 6.8
Malaria episodes per woman† None 1565 67.2
1 episode 694 29.8
2 episodes 65 2.8
3 episodes 6 0.3
Visits per malaria episode‡ 1 visit 767 91.1
2 visits 72 8.6
3 visits 3 0.4
*Number of pregnant women with criteria for blood collection and 
complete laboratory results
† Defined as P falciparum parasitaemia plus criteria for blood 
collection. Total of 842 malaria episodes
Table 1: Characteristics of the pregnant women attending the 
maternity clinic
N = 3129 *
n%
Age category (years) <20 837 27.0
20–34 1982 63.9
≥35 283 9.1
Trimester† 1st 708 22.8
2nd 797 25.6
3rd 1605 51.6
Parity nulliparous 403 12.9
1 to 3 1896 60.7
≥4 824 26.4
Season‡ Dry season 1371 43.8
Wet season 1757 56.2
Signs and symptoms n %
Current Fever¶ 377 12.1
Fever or history of fever ** 2044 65.4
Arthromyalgias 2339 74.8
Headache 2706 86.5
Convulsions 13 0.4
Pallor 218 7.0
* Number of first or only visits made by pregnant women with criteria 
for blood collection and complete laboratory results
† 1st trimester: 0–12 weeks; 2nd trimester: 13–24 weeks; 3rd 
trimester: 25–40 weeks
‡ Wet season: November to April; Dry season: May to October
¶Axillary temperature ≥ 37.5°C
** Axillary temperature ≥ 37.5°C and/or history of fever in the last 24 
hours
Table 2: Proportion of visits with P falciparum asexual 
parasitaemia and anemia
N = 3129 *
n%
P falciparum asexual parasitaemia 842 26.9
Moderate anemia† 1659 53.0
Severe anemia‡ 77 2.5
Very severe anemia§ 19 0.6
* Number of first or only visits made by pregnant women with criteria 
for blood collection and complete laboratory results
† Moderate anemia: hematocrit = 21–32%
‡ Severe anemia: hematocrit = 16–20%
§Very severe anemia: hematocrit ≤15%Malaria Journal 2008, 7:27 http://www.malariajournal.com/content/7/1/27
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of analyzed signs and symptoms in relation to P. falci-
parum  parasitaemia. Generally, all signs and symptom
had low predictive values (less than 40%) with the excep-
tion of current fever (PPV 50% 95% CI 45–56%). How-
ever, the prevalence of this sign was low (12%). The
association of signs and symptoms with malaria parasitae-
mia did not vary when the analysis was done by gesta-
tional age (data not shown). Combining arthromyalgias,
headache and fever or history of fever did not improve the
positive predictive value of parasitaemia (PPV 35%
95%CI 33–37%).
Discussion
In this rural area of Mozambique the majority (77.4%) of
pregnant women attending the maternity clinic with clin-
ical complaints had signs or symptoms suggestive of
malaria. However, less than a third (26.9%) of cases had
microscopically confirmed parasitaemia. Nearly a quarter
of the clinic visits with an illness indicative of malaria
were made by women in their first trimester of pregnancy.
These findings are relevant given the limited resources
dedicated to healthcare in rural Africa, because the major-
ity of pregnant women do not have access to parasitolog-
ical diagnosis, and they usually receive presumptive
treatment, leading to unnecessary drug exposure.
Primigravidae women made fewer visits to the maternity
clinic than other parities. This may be due to sociological
factors such as awareness of the risks of being sick during
pregnancy or lower social capacity for decision-making.
There were more women attending the clinic during the
rainy season, suggesting that malaria has a role in mater-
nal morbidity in this area.
One out of four women visited the clinic more than once
during the same pregnancy, indicating that morbidity
may be concentrated in a specific group of individuals.
This has been observed in children in relation to malaria
[18]. Nearly 10% of women came more than once within
the same confirmed malaria episode. This may be due to
recrudescence of the initial parasitaemia, although this
can not be confirmed without molecular analysis. Con-
sistent with previous reports, these findings showed that
younger age, lower parity and wet season were independ-
ently associated with an increased risk of P. falciparum par-
asitaemia, while first trimester was associated with a
reduced risk [11,19-22].
Information about the clinical presentation of malaria
episodes during pregnancy in stable transmission areas is
surprisingly limited or incomplete [10,23]. Most of the
data comes from low endemic areas [24-26]. Further-
Table 5: Positive predictive value of clinical signs and symptoms 
for P falciparum parasitaemia in 3129* visits made by pregnant 
women
Signs/symptoms n % PPV† (%) (95%CI)
Current fever‡ 377 12.1 50 (45–56)
Fever or history of fever§ 2044 65.4 33 (31–35)
Arthromyalgias 2339 74.8 29 (28–31)
Headache 2706 86.5 28 (27–30)
Convulsions 13 0.4 23 (5.0–54)
Pallor 218 7.0 27 (21–33)
* Number of first or only visits of pregnant women with criteria for 
blood collection and complete laboratory results
† Positive Predictive Value
‡ Axillary temperature ≥ 37.5°C
§Axillary temperature ≥ 37.5°C and/or history of fever in the last 24 
hours
Table 4: P falciparum malaria in pregnant women
N = 3129* Univariate OR† (95%CI) Multivariate OR‡ (95%CI)
Age category (years) <20 1.00 -- 1.00 --
20–34 0.58 (0.49–0.70) 0.70 (0.57–0.86)
≥35 0.42 (0.30–0.58) 0.58 (0.38–0.87)
Parity nulliparous 1.00 -- 1.00 --
1 to 3 0.62 (0.50–0.78) 0.75 (0.58–0.96)
4 or > 0.43 (0.33–0.56) 0.65 (0.47–0.91)
Season§ Dry season 1.00 -- 1.00 --
Wet season 1.67 (1.42–1.97) 1.63 (1.37–1.93)
Trimester ¶ 1st 1.00 -- 1.00 --
2nd 1.91 (1.49–2.43) 1.87 (1.45–2.42)
3rd 1.80 (1.44–2.24) 1.82 (1.44–2.28)
Previous malaria episodes 1.44 (1.11–1.85) 1.37 (1.05–1.79)
* Number of first or only visits made by pregnant women with criteria for blood collection and complete laboratory results
† OR = Odds Ratio
‡ Global model considering fever or history of fever
§ Wet season: November to April; Dry season: May to October
¶ 1st trimester: 0–12 weeks; 2nd trimester: 13–24 weeks; 3rd trimester: 25–40 weeksMalaria Journal 2008, 7:27 http://www.malariajournal.com/content/7/1/27
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more, there is a lack of information on the association
between peripheral parasitaemia and the presence of signs
and symptoms of malaria during pregnancy. A study car-
ried out in a stable transmission area of Sudan suggested
that maternal history can accurately predict malaria epi-
sodes during pregnancy, justifying the presumptive treat-
ment of the clinical presentation [27].
In contrast, these findings suggest the opposite. All clini-
cal signs and symptoms evaluated had low positive pre-
dictive values. Only the presence of fever had a PPV of
50% (95% CI 45–56%), however its prevalence among
women was very low. The majority of women presenting
a sign or symptom suggestive of malaria did not have par-
asitaemia, and clinical complaints had a relatively low
value in guiding the treatment of malaria in the absence
of parasitological diagnosis. The simultaneous occurrence
of the most frequently presented signs and symptoms
(headache, arthromyalgias and history of recent fever) did
not substantially increase the PPV (35%, 95% CI
33–37%) for malaria parasitaemia. This study was
focused in women who presented with predefined symp-
toms, and thus it was not possible to calculate their sensi-
tivity and specificity. This may be seen as a limitation of
the study. However, the aim was to describe the clinical
presentation of malaria parasitaemia in pregnant women
attending the maternity clinic because they have clinical
complaints. Asymptomatic pregnant women although
may also be parasitaemic, are unlikely to attend a health
facility except for antenatal routine control visits.
Conclusion
Although presumptive malaria treatment has been recom-
mended by WHO as a malaria control measure in
endemic areas [12,28], this strategy should be reconsid-
ered for malaria in pregnancy given the lack of available
antimalarial drugs with acceptable safety profiles. This is
especially critical during the first trimester due to concerns
from animal data about the safety of artemisinin deriva-
tives in pregnancy [29]. The current recommendation is to
give artemisinin-based combinations (ACTs) as the first
line treatment for uncomplicated malaria for women in
the second and third trimesters and as second line treat-
ment in the first trimester [12]. Careful evaluation of drug
safety is urgent as countries adopt this policy.
Due to the absence of safe alternatives to failing drugs,
case management of uncomplicated malaria during preg-
nancy poses one of the greatest challenges to malaria con-
trol. Increasing the accessibility to diagnostic tools is
needed to identify positive cases and to avoid unnecessary
administration of drugs. The use of rapid diagnostic tests
(RDTs) is one option to reduce overtreatment in areas
where microscopy facilities are absent. RDTs are being
increasingly promoted, however, their implementation is
still limited by their cost, and they will have distribution
and life span issues that need consideration. As we
improve the tools for malaria control, finding antimalar-
ials that are safe for pregnant women with no restriction
by gestational age remains a public health priority.
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